Ranbezolid

Ranbezolid (RBx7644 free base) is an orally active, oxazolidinone antibiotic against Gram-positive and Gram-negative anaerobes including Staphylococcus aureus, Staphylococcus epidermidis and Bacteroides fragilis. Ranbezolid can inhibit the 50s ribosomal subunit with an IC50 of 17 μM for bacterial ribosomes. Ranbezolid interferes cell wall and lipid synthesis. Ranbezolid can rapidly kill bacteria, significantly reduce bacterial load, and has better cardiovascular safety. Ranbezolid can be used for the study of antibiotics for anaerobic bacteria[1][2][3].

Product Specifications

CAS Number

[392659-38-0]

Product Name Alternative

RBx7644 (free base)

UNSPSC

12352005

Target

Antibiotic; Bacterial

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cardiovascular Disease

Smiles

CC(NC[C@H]1CN(C2=CC=C(N3CCN(CC4=CC=C([N+]([O-])=O)O4)CC3)C(F)=C2)C(O1)=O)=O

Molecular Formula

C21H24FN5O6

Molecular Weight

461.44

References & Citations

[1]Kalia V, et al. Mode of action of Ranbezolid against staphylococci and structural modeling studies of its interaction with ribosomes. Antimicrob Agents Chemother. 2009 Apr;53 (4) :1427-33.|[2]Mathur T, et al. Anti-anaerobic potential of ranbezolid: insight into its mechanism of action against Bacteroides fragilis. Int J Antimicrob Agents. 2013 Jan;41 (1) :36-40.|[3]Naruganahalli KS, et al. Ranbezolid, a novel oxazolidinone antibacterial: in vivo characterisation of monoamine oxidase inhibitory potential in conscious rats. Eur J Pharmacol. 2006 Sep 18;545 (2-3) :167-72.